All times are listed in CEST (Central European Summer Time)
Found 2 Presentations For Request "Abs: 170P"
170P - β2-adrenergic receptor gene expression as a prognostic and predictive biomarker in HER2-positive early-stage breast cancer patients enrolled on the NCCTG-N9831 (Alliance) trial
- Rafael Caparica (Brussels, Belgium)
Abstract
Background
β2-adrenergic receptor (ADRB2) modulates immune activation, and may enhance the activity of trastuzumab in HER2-positive breast cancer cells. We assessed the impact of
Methods
NCCTG-N9831 compared chemotherapy (arm A) versus chemotherapy plus trastuzumab (arms B&C) as adjuvant treatment of HER2-positive early-stage breast cancer patients. Disease-free survival (DFS) was the primary endpoint. Gene expression data by DASL Assay were matched to patient’s characteristics. Median
Results
Conclusions
These results suggest that ADRB2 expression is associated with a favorable prognosis and could identify a subset of HER2-positive early-stage breast cancer patients who appear not to benefit from adjuvant trastuzumab.
Clinical trial identification
NCT00005970.
Legal entity responsible for the study
North Central Cancer Treatment Group (NCCTG)-N9831 trial. NCCTG is now part of the Alliance for Clinical Trials in Oncology (Alliance).
Funding
Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821, U10CA180882, and U24CA196171 (to the Alliance for Clinical Trials in Oncology). Genentech provided trastuzumab for this study. Also supported in part by funds from Genentech, Genomic Health, Breast Cancer Research Foundation; and Fondation Cancer Luxembourg (to F.R. and C.D.).
Disclosure
R. Caparica: Speaker Bureau/Expert testimony: Boehringer-Ingelheim; Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: AstraZeneca; Speaker Bureau/Expert testimony: Janssen; Travel/Accommodation/Expenses: Pfizer. A.H. Awada: Speaker Bureau/Expert testimony: Roche; Speaker Bureau/Expert testimony: Lilly; Speaker Bureau/Expert testimony: Amgen; Speaker Bureau/Expert testimony: ESAI; Speaker Bureau/Expert testimony: BMS; Speaker Bureau/Expert testimony: Pfizer; Speaker Bureau/Expert testimony: Novartis; Speaker Bureau/Expert testimony: MSD. M. Piccart: Honoraria (institution), Officer/Board of Directors: Radius; Honoraria (self), Honoraria (institution): AstraZeneca; Honoraria (self), Honoraria (institution): Lilly ; Honoraria (self), Honoraria (institution): MSD; Honoraria (self), Honoraria (institution): Novartis; Honoraria (self): Odonate; Honoraria (self), Honoraria (institution): Pfizer; Honoraria (self), Honoraria (institution): Roche; Honoraria (self): Crescendo biologics; Honoraria (self): Periphagen; Honoraria (self): Huya; Honoraria (self): Debiopharm; Honoraria (self): PharmaMar; Honoraria (self): G1 therapeutics; Honoraria (self): Menarini; Honoraria (self): Seattle Genetics; Honoraria (self): Immunomedics; Honoraria (institution): Synthon; Honoraria (institution): Servier. E. Perez: Honoraria (institution): NIH; Honoraria (institution): Roche. A. Moreno-Aspitia: Honoraria (institution): NIH; Honoraria (institution): Roche. S. Badve: Speaker Bureau/Expert testimony: Targos; Speaker Bureau/Expert testimony: MSD; Speaker Bureau/Expert testimony: Natera; Honoraria (institution): Dako/Agilent; Honoraria (institution): Roche/Ventana. E. de Azambuja: Honoraria (self), Honoraria (institution), Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Travel/Accommodation/Expenses: Glaxo. All other authors have declared no conflicts of interest.
1165P - Subgroup analysis by Ki-67 and primary tumour origins of the randomized, placebo-controlled phase III study of surufatinib in advanced well-differentiated extrapancreatic neuroendocrine tumours (SANET-ep)
- Zhiwei Zhou (Guangzhou, China)
Abstract
Background
Surufatinib, a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (1,2,3), fibroblast growth factor receptor 1 and colony stimulating factor 1 receptor, has demonstrated superior efficacy in extrapancreatic neuroendocrine tumors (NETs) in a phase III study (SANET-ep, ESMO 2019 Abs. LBA76). The proliferation marker Ki-67 and primary tumor origins are the major prognostic factors in NETs.
Methods
The post-hoc efficacy analysis of surufatinib versus placebo was conducted by Ki-67 subcategory (<3%, 3-10%, >10%) and primary tumor origins (foregut, midgut, hindgut, others or unknown) in patients (pts) with advanced well-differentiated (grade 1 or 2) extrapancreatic NETs. The primary endpoint (progression-free survival [PFS]) and secondary endpoint (objective response rate [ORR]) both by investigator assessment (RECIST1.1) were analyzed.
Results
Median PFS was significantly prolonged with surufatinib compared to placebo in subgroups of Ki-67 3-10% (7.6 vs 4.6 months [mo], hazard ratio [HR] 0.47,
Conclusions
Surufatinib demonstrated clinically significant benefits for pts with advanced well-differentiated extrapancreatic NETs compared to placebo. Results of this exploratory analysis were consistent with those reported for the SANET-ep primary analysis, and improved outcomes were observed across major subgroups.
Clinical trial identification
NCT02588170.
Legal entity responsible for the study
Hutchison MediPharma Limited.
Funding
Hutchison MediPharma Limited.
Disclosure
J. Li, J. He: Full/Part-time employment: Hutchison MediPharma Limited. W. Su: Shareholder/Stockholder/Stock options, Full/Part-time employment: Hutchison MediPharma Limited. All other authors have declared no conflicts of interest.